Novo Nordisk filed 14 new lawsuits against compounders claiming to contain semaglutide, the component of its Ozempic and ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Popular digital weight loss app, Noom (NOOM) undercuts Novo Nordisk's Wegovy by offering quarter-dose packs at $119 for the ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.